中国首个!丽珠医药KCNQ2/3 激动剂NS-041抑郁症临床试验申请获受理

丽珠医药
Oct 22, 2025

丽珠医药(深交所代码: 000513;香港联交所代码: 01513)宣布,公司1类创新药NS-041用于治疗抑郁症的临床试验申请(IND),已于近日获国家药品监督管理局(NMPA)正式受理。NS-041是一款新型高选择性KCNQ2/3激动剂,此次申报是其继癫痫之后的第二项适应症。抑郁症是一种以持续情绪低落和兴趣减退为核心症状的常见精神障碍。抑郁症是目前全球第四大疾病,患者人数约3.3亿。在中国,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10